Nano-drug delivery system with enhanced tumour penetration and layered anti-tumour efficacy

Nanomedicine. 2022 Sep:45:102592. doi: 10.1016/j.nano.2022.102592. Epub 2022 Jul 27.

Abstract

The low delivery efficiency of nano-drugs and limited tumour penetration are still huge challenges in treating solid tumours. Herein, we developed a pH-responsive nano-drug delivery system, CALS/PDMA@DOX, with a size conversion-layered delivery function. The system is composed of a pH-responsive cationic liposome loaded with DOX (CALS) and a polyamidoamine dendrimer loaded with DOX (PAMAM@DOX) modified with 2,3-dimethylmaleic anhydride (PDMA@DOX) using electrostatic adsorption. In the tumour microenvironment, the positively-charged large-size CALS and the positively-charged small-size PAMAM@DOX were dissociated to exert anti-tumour effects. CALS preferentially targeted tumour angiogenesis endothelial cells. Because of its small size and positive charge, PAMAM@DOX showed excellent tumour penetration. Significant tumour suppression by the system in vivo was confirmed in a 4T1 tumour xenograft mouse model. This pH-triggered size-switching layered delivery nanosystem is a safe and effective cancer treatment delivery platform that improves drug permeability and therapeutic efficacy.

Keywords: Cationic liposomes; PAMAM; Size changeable; Tumour penetration; pH-responsive.

MeSH terms

  • Animals
  • Cell Line, Tumor
  • Dendrimers*
  • Doxorubicin / pharmacology
  • Doxorubicin / therapeutic use
  • Drug Carriers
  • Drug Delivery Systems
  • Endothelial Cells / pathology
  • Humans
  • Hydrogen-Ion Concentration
  • Liposomes
  • Mice
  • Nanoparticle Drug Delivery System
  • Nanoparticles* / therapeutic use
  • Neoplasms* / drug therapy
  • Neoplasms* / pathology
  • Tumor Microenvironment

Substances

  • Dendrimers
  • Drug Carriers
  • Liposomes
  • Nanoparticle Drug Delivery System
  • Doxorubicin